The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor

Sandra S. Hammer, Eleni Beli, Nermin Kady, Qi Wang, Kiana Wood, Todd A. Lydic, Goldis Malek, Daniel R. Saban, Xiaoxin X. Wang, Sugata Hazra, Moshe Levi, Julia V. Busik, Maria B. Grant

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy, a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/LXRβ) prevents DR in diabetic animal models. LXRs are nuclear receptors that play key roles in regulating cholesterol metabolism, fatty acid metabolism and inflammation. In this manuscript, we show insight into DR pathogenesis by demonstrating an innovative signaling axis that unifies key metabolic regulators, Sirtuin 1 and LXR, in modulating retinal cholesterol metabolism and inflammation in the diabetic retina. Expression of both regulators, Sirtuin 1 and LXR, are significantly decreased in diabetic human retinal samples and in a type 2 diabetic animal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inflammation, reduces pro-inflammatory macrophages activity and prevents the formation of diabetes-induced acellular capillaries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.

Original languageEnglish (US)
Pages (from-to)181-190
Number of pages10
JournalEBioMedicine
Volume22
DOIs
StatePublished - Aug 1 2017

Fingerprint

Sirtuin 1
Diabetic Retinopathy
Metabolism
Liver
Cholesterol
Medical problems
Lipids
Animals
Chemical activation
Drug therapy
Macrophages
Cytoplasmic and Nuclear Receptors
Inflammation
Fatty Acids
Animal Models
Blindness
Dyslipidemias
Liver X Receptors
Retina
Therapeutics

Keywords

  • Bone marrow
  • Cholesterol efflux
  • Cholesterol metabolism
  • Circulating angiogenic cells
  • Diabetic retinopathy
  • Dyslipidemia
  • Glucose
  • Liver X receptor
  • Retinal endothelial cells
  • Retinal inflammation
  • Reverse cholesterol transport
  • SIRT1
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor. / Hammer, Sandra S.; Beli, Eleni; Kady, Nermin; Wang, Qi; Wood, Kiana; Lydic, Todd A.; Malek, Goldis; Saban, Daniel R.; Wang, Xiaoxin X.; Hazra, Sugata; Levi, Moshe; Busik, Julia V.; Grant, Maria B.

In: EBioMedicine, Vol. 22, 01.08.2017, p. 181-190.

Research output: Contribution to journalArticle

Hammer, SS, Beli, E, Kady, N, Wang, Q, Wood, K, Lydic, TA, Malek, G, Saban, DR, Wang, XX, Hazra, S, Levi, M, Busik, JV & Grant, MB 2017, 'The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor', EBioMedicine, vol. 22, pp. 181-190. https://doi.org/10.1016/j.ebiom.2017.07.008
Hammer, Sandra S. ; Beli, Eleni ; Kady, Nermin ; Wang, Qi ; Wood, Kiana ; Lydic, Todd A. ; Malek, Goldis ; Saban, Daniel R. ; Wang, Xiaoxin X. ; Hazra, Sugata ; Levi, Moshe ; Busik, Julia V. ; Grant, Maria B. / The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor. In: EBioMedicine. 2017 ; Vol. 22. pp. 181-190.
@article{43b9d190e94946adb8c91dac4ed49bd4,
title = "The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor",
abstract = "Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy, a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/LXRβ) prevents DR in diabetic animal models. LXRs are nuclear receptors that play key roles in regulating cholesterol metabolism, fatty acid metabolism and inflammation. In this manuscript, we show insight into DR pathogenesis by demonstrating an innovative signaling axis that unifies key metabolic regulators, Sirtuin 1 and LXR, in modulating retinal cholesterol metabolism and inflammation in the diabetic retina. Expression of both regulators, Sirtuin 1 and LXR, are significantly decreased in diabetic human retinal samples and in a type 2 diabetic animal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inflammation, reduces pro-inflammatory macrophages activity and prevents the formation of diabetes-induced acellular capillaries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.",
keywords = "Bone marrow, Cholesterol efflux, Cholesterol metabolism, Circulating angiogenic cells, Diabetic retinopathy, Dyslipidemia, Glucose, Liver X receptor, Retinal endothelial cells, Retinal inflammation, Reverse cholesterol transport, SIRT1, Tumor necrosis factor alpha",
author = "Hammer, {Sandra S.} and Eleni Beli and Nermin Kady and Qi Wang and Kiana Wood and Lydic, {Todd A.} and Goldis Malek and Saban, {Daniel R.} and Wang, {Xiaoxin X.} and Sugata Hazra and Moshe Levi and Busik, {Julia V.} and Grant, {Maria B.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ebiom.2017.07.008",
language = "English (US)",
volume = "22",
pages = "181--190",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor

AU - Hammer, Sandra S.

AU - Beli, Eleni

AU - Kady, Nermin

AU - Wang, Qi

AU - Wood, Kiana

AU - Lydic, Todd A.

AU - Malek, Goldis

AU - Saban, Daniel R.

AU - Wang, Xiaoxin X.

AU - Hazra, Sugata

AU - Levi, Moshe

AU - Busik, Julia V.

AU - Grant, Maria B.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy, a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/LXRβ) prevents DR in diabetic animal models. LXRs are nuclear receptors that play key roles in regulating cholesterol metabolism, fatty acid metabolism and inflammation. In this manuscript, we show insight into DR pathogenesis by demonstrating an innovative signaling axis that unifies key metabolic regulators, Sirtuin 1 and LXR, in modulating retinal cholesterol metabolism and inflammation in the diabetic retina. Expression of both regulators, Sirtuin 1 and LXR, are significantly decreased in diabetic human retinal samples and in a type 2 diabetic animal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inflammation, reduces pro-inflammatory macrophages activity and prevents the formation of diabetes-induced acellular capillaries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.

AB - Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy, a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/LXRβ) prevents DR in diabetic animal models. LXRs are nuclear receptors that play key roles in regulating cholesterol metabolism, fatty acid metabolism and inflammation. In this manuscript, we show insight into DR pathogenesis by demonstrating an innovative signaling axis that unifies key metabolic regulators, Sirtuin 1 and LXR, in modulating retinal cholesterol metabolism and inflammation in the diabetic retina. Expression of both regulators, Sirtuin 1 and LXR, are significantly decreased in diabetic human retinal samples and in a type 2 diabetic animal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inflammation, reduces pro-inflammatory macrophages activity and prevents the formation of diabetes-induced acellular capillaries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.

KW - Bone marrow

KW - Cholesterol efflux

KW - Cholesterol metabolism

KW - Circulating angiogenic cells

KW - Diabetic retinopathy

KW - Dyslipidemia

KW - Glucose

KW - Liver X receptor

KW - Retinal endothelial cells

KW - Retinal inflammation

KW - Reverse cholesterol transport

KW - SIRT1

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=85026353637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026353637&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2017.07.008

DO - 10.1016/j.ebiom.2017.07.008

M3 - Article

AN - SCOPUS:85026353637

VL - 22

SP - 181

EP - 190

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -